ASX 52-Week Lows: Mixed Results Highlight Challenges Across Retail, Healthcare, and Resources
A quick review of stocks trading near 52 week low comes handy in more than one way. Not just a stock sentiment indicator, though reflecting a bearish sentiment, it can also locate oversold positions which offer potential buying opportunities. Contrarian investors and even seasoned ones hunt for such undervalued stocks as they believe in its potential to bounce back when the market or sector recovers, thus reaping significant gains.
has reported weak results for FY25. Sales revenue declined by 1% to $8.978B and EBIT declined by 20% to $548 million. This can be viewed as a reflection of softening of demand which is seen across Australia, New Zealand and the US. Earnings per share dropped by 24% to 49 cents. However, the company was successful in maintaining discipline in capital expenditure. Reece is now focusing on operational efficiency and streamlining corporate costs. A final fully franked dividend of 11.86 cents per share was declared. Looking ahead, Reece is anticipating a slow recovery but is committed to navigating the cycle while investing in its network and digital capabilities.
Micheal Hill International (ASX: MHJ)
has reported a challenging FY25 as it is facing continuous economic uncertainty along with tough retail condition across all regions. Group revenue remained almost flat at $643.7M but EBIT slipped slightly. The company was hit by a significant $7.4M impairment on the Bevilles brand reflecting the challenges in that segment. Store closure outnumbered openings, bringing down the network from 300 to 287 stores. New Zealand sales declined by 5.5% while Canada saw modest growth. Australia’s gains were muted and weighed down by operational difficulties. Record high gold prices squeezed margins and the ongoing volatile market environment dampened performance.
Cardiex Limited (ASX: CDX)
reported some progress in June quarter amid ongoing challenges. Pulse arterial health monitor sales reached $0.7 million for the year and the units sold exceeded 2,100. Consumer concerns about the $350 price tag and usability issues such as outdated charging ports and lack of multi-user support persist. Corporate costs remain significant with operating cash outflows increasing despite cost cutting efforts. The company’s expanded clinical footprint and evolution towards subscription-based models are still in early stage.
Sonic Healthcare’s (ASX: SHL)
FY25 results reflect ongoing challenges. Net profit remained almost flat rising only 0.5% to $514 million. This indicated pressure on profitability. The company faced increased expenses including a 24% jump in net interest costs due to acquisitions and higher interest rates. EBITDA margins showed only slight improvement amid cost efficiency efforts. Rising depreciation and amortisation expenses along with higher borrowing costs had its impact heavily. Recent acquisitions like LADR will add burdens in FY26 and FY27 before delivering expected synergies. The company’s net tangible asset backing remained negative suggesting underlying asset quality concerns.
faced a tough quarter ended June 2025 with ongoing costs outweighing progress. The first-pass aircore drilling at Tengrela South showed promising intercepts but fresh bedrock remains untested leaving substantial uncertainty. Cash outflows continue with operating activities consuming $440,000 this quarter and a total of $1.63 million year to date. This put a strain on already limited cash reserves of just $1.92 million. The company depends on successful equity raises planned for H2 2025 to maintain operations.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
